Imatinib mesylate in chordoma

Cancer

Volumn 101, Issue 9, 2004, Pages 2086-2097

  Casali, Paolo G ^a   Messina, Antonella ^a   Stacchiotti, Silvia ^a   Tamborini, Elena ^a   Crippa, Flavio ^a   Gronchi, Alessandro ^a   Orlandi, Rosaria ^a   Ripamonti, Carla ^a   Spreafico, Carlo ^a   Bertieri, Raffaello ^b   Bertulli, Rossella ^a   Colecchia, Maurizio ^a   Fumagalli, Elena ^a   Greco, Angela ^a   Grosso, Federica ^a   Olmi, Patrizia ^a   Pierotti, Marco A ^a,c   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Novartis Pharma   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Chordoma; Imatinib mesylate; Platelet derived growth factor receptor (PDGFRB); Response; Tyrosine kinase inhibitor

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHORDOMA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GLUCOSE TRANSPORT; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; CHORDOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PHOSPHORYLATION; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 20844459809     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20618     Document Type: Article

References (25)

1. McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control. 2001;12:1-11.
2. Mirra JM, Nelson SD, Della Rocca C, et al. Chordoma. In: Fletcher CDM, Unni KK, Mertens F, editors. Pathology and genetics: tumors of soft tissue and bone. World Health Organization classification of tumors. Lyon: IARC Press, 2002:316-317.
3. Baratti D, Gronchi A, Pennacchioli E, et al. Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Oncol. 2003;10:291-296.
4. Stener B, Gunterberg B. High amputation of the sacrum for extirpation of tumors. Principles and technique. Spine. 1978;3:351-366.
5. Bergh P, Kindblom LG, Gunterberg B, et al. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer. 2000;88:2122-2134.
6. York JE, Kaczaraj A, Abi-Said D, et al. Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery. 1999;44:74-79.
7. Fagundes MA, Hug EB, Liebsch NJ, et al. Radiation therapy for chordomas of the base of skull and cervical spine: patterns of failure and outcome after relapse. Int J Radiat Oncol Biol Phys. 1995;33:579-584.
8. Debus J, Schulz-Ertner D, Schad L, et al. Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base. Int J Radiat Oncol Biol Phys. 2000;47:591-596.
9. Hug EB, Slater JD. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. Neurosurg Clin N Am. 2000;11:627-638.
10. Noel G, Habrand JL, Mammar H, et al. Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: the Centre de Proton-therapie D'Orsay experience. Int J Radiat Oncol Biol Phys. 2001;51:392-398.
11. Schulz-Ertner D, Haberer T, Jakel O, et al. Radiotherapy for chordomas and low-grade chondrosarcomas of the skull base with carbon ions. Int J Radiat Oncol Biol Phys. 2002;53:36-42.
12. Azzarelli A, Quagliuolo V, Cerasoli S, et al. Chordoma: natural history and treatment results in 33 cases. J Surg Oncol 1988;37:185-191.
13. Scimeca PG, James-Herry AG, Black KS, et al. Chemotherapeutic treatment of malignant chordoma in children. J Pediatr Hematol Oncol. 1996;18:237-240.
14. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
15. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
16. Van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002;38(Suppl 5):S83-S87.
17. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052-1056.
18. Verweij J, Casali PG, Zalcberg J, et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG [abstract]. Proc Am Soc Clin Oncol. 2003;22:816.
19. Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results [abstract]. Proc Am Soc Clin Oncol 2003;22:816.
20. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
21. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 2002;20:3586-3591.
22. Mace J, Biermann JS, Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer. 2002;95:2373-2379.
23. Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012-2020.
24. Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumors. Lancet Oncol. 2002;3:655-664.
25. Choi H, Charnsangavej C, Macapinlac HA, et al. Correlation of computerized tomography (CT) and proton emission tomography (PET) in patients with metastatic GIST treated at a single institution with imatinib mesylate [abstract]. Proc Am Soc Clin Oncol. 2003;22:819.